This is in good agreement with the recent finding that patients’ HLA class I genotype (HLA heterozygosity) influences response to checkpoint inhibitor therapy presumably due to efficient HLA presentation of tumor antigens triggering efficient CD8+ T-cell responses [147]. The gene discussed is CD8A; the disease is neoplasm.